Abstract
Introduction: Anemia, as a common complication of end-stage renal disease (ESRD), usually
develops due to erythropoietin deficiency. Recombinant human erythropoietins (rHEPOs)
are indicated for the correction of renal anemia.
Objectives: We aimed to evaluate the efficacy of a new brand of erythropoietin named
CinnaPoietin (erythropoietin beta) on hemoglobin levels.
Patients and Methods: This is a randomized double-blinded controlled trial. Ninety-six
ESRD patients on hemodialysis recruited in the study, whose hemoglobin levels was less than
10 g/dL. They allocated to two groups. PDPoetin (erythropoietin alfa) 50-100 U/kg three
times per week intravenously administrated to the control group and CinnaPoietin with
exactly same regimen as like PDPoetin group administrated for the rest of the participants.
The study duration was 3 months. We measured plasma hemoglobin monthly for 3 months.
Results: We found, hemoglobin was increased across the time and it was statistically
significant (P<0.001), while there was no statistically significant differences between the
groups (P=0.712).
Conclusion: According to the result of the present study there is no statistical significant
difference between these two brands of exogenous rHEPO in the case of increasing the
hemoglobin concentration.